Navigation Links
Advanced Life Sciences to Host 2010 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
Date:3/17/2011

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Teysuno™ (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
2. Greg Miller of Advanced Health Media Named New Jersey Technology Council CIO of the Year
3. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
4. Lab-on-a-Chip - ICAP Ocean Tomo Announces Auction of Patents for Advanced Techniques in Bio-Organic Analysis and Synthesis
5. Salk Institute Celebrates Grand Opening of the Waitt Advanced Biophotonics Center
6. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
7. Advanced Health Media Company Announces Renee DeFranco as Senior Vice President - Human Resources
8. New materials may bring advanced optical technologies, cloaking
9. Advanced Pain Remedies, a Subsidiary of Cato BioVentures, Announces a Three Million Dollar Award from the National Cancer Institute for SP-SAP
10. Advanced BioHealing to Present at 29th Annual J.P. Morgan Healthcare Conference
11. Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 AACC welcomed thousands ... 2015 AACC Annual Meeting & Clinical Lab Expo ... 26–30. The meeting showcased revolutionary advancements in clinical ... of healthcare providers to diagnose patients quickly and ... treatment. As of Wednesday, July ...
(Date:7/30/2015)... Texas (PRWEB) , ... July 30, 2015 , ... The ... and in-depth study on the current state of the global Propanol market with a ... Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch ...
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Cedara Software , a Merge Healthcare ... has released a new version of its digital imaging ... product is a software development kit (SDK) that now ... connectivity for software applications. , ,DICOM is a set ...
... your building technologically obsolete? Are you paying too much ... a building is very important in the selection process ... to current tenants who are contemplating a move to ... some should be avoided because they offer nothing in ...
... all relevant domain names and misspellings pertaining to its trademark? ... are they free for the taking? Who has rights to ... questions posed by a reader regarding domains in his portfolio. ... principles can be used as guidelines with respect to whether ...
Cached Biology Technology:Making sure YourSpace is technologically sound 2Making sure YourSpace is technologically sound 3Making sure YourSpace is technologically sound 4Making sure YourSpace is technologically sound 5Is your business domain at risk? 2Is your business domain at risk? 3Is your business domain at risk? 4
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... behavior through tiny hairs on the cell surface called cilia. ... not work properly. New research from UC Davis published this ... new insights into how these cilia are assembled. "It,s ... Jonathan Scholey, professor of molecular and cellular biology at UC ...
... Iowa - Bone is one of nature,s surprising "building ... resilient. Scientists at the U.S. Department of Energy,s ... its outstanding properties and the important role citrate plays, ... or prevent bone diseases such as osteoporosis. Using ...
... The world,s largest and least known type of gorilla ... has awarded the Wildlife Conservation Society a $150,000 grant to ... eastern Democratic Republic of Congo. The grant will ... struggle to protect the gorillas of Kahuzi-Biega National Park, a ...
Cached Biology News:How cells' sensing hairs are made 2Citrate key in bone's nanostructure 2Citrate key in bone's nanostructure 3Wildlife Conservation Society receives $150,000 grant from Newman's Own Foundation to save gorillas 2
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Biology Products: